Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hosp...
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
...
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3221
- Registration Number
- NCT00452530
- Locations
- 🇬🇧
Local Institution, Epsom, Surrey, United Kingdom
Thromboprophylaxis and Bariatric Surgery
- Conditions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- University Hospital, Strasbourg, France
- Target Recruit Count
- 300
- Registration Number
- NCT00444652
- Locations
- 🇫🇷
Département d'Anesthésiologie Hôpital Civil, Strasbourg, Alsace, France
🇫🇷Clinique de l'Orangerie, Strasbourg, Alsace, France
🇫🇷Laboratoire d'hémostase Hôpital de Hautepierre, Strasbourg, Alsace, France
Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- University of Iowa
- Target Recruit Count
- 2
- Registration Number
- NCT00426127
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5407
- Registration Number
- NCT00423319
- Locations
- 🇺🇸
Shrock Orthopedic Research, Ft. Lauderdale, Florida, United States
🇺🇸Orthoarkansas, P.A., Little Rock, Arkansas, United States
🇺🇸Pab Clinical Research, Brandon, Florida, United States
Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery
- Conditions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- G. d'Annunzio University
- Target Recruit Count
- 43
- Registration Number
- NCT00420667
- Locations
- 🇮🇹
Institute of Cardiology - S. Camillo Hospital, Chieti, CH, Italy
Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism
- Conditions
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00413374
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement
- First Posted Date
- 2006-12-06
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 367
- Registration Number
- NCT00408239
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
- Conditions
- Interventions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2009-05-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 726
- Registration Number
- NCT00398905
Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
- Conditions
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 877
- Registration Number
- NCT00396786
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Portola Pharmaceuticals
- Target Recruit Count
- 215
- Registration Number
- NCT00375609
- Locations
- 🇨🇦
Montreal General Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.